← Back to guidelines
Obstetrics5 papers

Streptococcus agalactiae infection

Last edited: 1 h ago

Overview

Streptococcus agalactiae, also known as Group B Streptococcus (GBS), is a gram-positive bacterium that can cause a range of infections in both humans and animals, particularly in neonates and immunocompromised individuals. In humans, GBS is a significant cause of neonatal sepsis, meningitis, and pneumonia, often transmitted during vaginal delivery from an infected mother. In livestock, particularly in tilapia farming and small ruminants, GBS leads to substantial economic losses due to morbidity and mortality associated with mastitis, septicemia, and other systemic infections. Understanding the epidemiology and clinical implications of GBS infections is crucial for timely intervention and prevention strategies. This knowledge is essential in day-to-day practice for clinicians managing pregnant women, neonates, and livestock to mitigate the risks and impacts of GBS infections effectively 13.

Pathophysiology

The pathogenesis of Streptococcus agalactiae infections involves several key mechanisms that lead to clinical manifestations across different hosts. In humans, GBS adheres to host epithelial cells via surface proteins such as C5a peptidase and beta-hemolysin, facilitating colonization and invasion. Once established, the bacteria can trigger robust inflammatory responses, mediated by cytokines like IL-8 and IL-12, which contribute to tissue damage and systemic spread. In neonates, the immature immune system exacerbates susceptibility, often leading to severe sepsis and meningitis due to the overwhelming inflammatory response and lack of protective antibodies 1.

In livestock, particularly tilapia and small ruminants, GBS infection disrupts mucosal barriers and triggers innate immune responses characterized by enhanced activities of antioxidant enzymes (SOD, ACP, CAT) and increased expression of MHC molecules and immunoglobulins (IgM, IgT). These immune responses aim to neutralize the pathogen but can also cause collateral damage to tissues, leading to systemic infections such as mastitis and septicemia. The variability in susceptibility among different species and individuals often correlates with the strength and timing of these immune reactions 14.

Epidemiology

The epidemiology of Streptococcus agalactiae varies significantly across different populations and settings. In human populations, GBS colonization rates among pregnant women range from 10% to 30% globally, with notable regional variations. For instance, a study in Bukavu, Democratic Republic of Congo, reported a GBS colonization rate of 20% among pregnant women, influenced by factors such as low education, history of urinary infections, premature childbirth, and HIV positivity 3. In livestock, the prevalence of GBS infections is particularly high in dairy herds and tilapia farms, where outbreaks can devastate production. Economic losses due to contagious agalactia in small ruminants and mastitis in dairy sheep are substantial, with herd management practices and geographic regions playing significant roles in disease distribution 5. Trends indicate a gradual increase in antibiotic resistance among GBS isolates, necessitating vigilant monitoring and alternative prevention strategies 2.

Clinical Presentation

In neonates, clinical presentations of GBS infections can range from asymptomatic colonization to severe sepsis, pneumonia, and meningitis. Typical signs include fever, lethargy, poor feeding, apnea, and signs of sepsis such as tachypnea and tachycardia. Atypical presentations might include localized infections like omphalitis or late-onset sepsis presenting with gastrointestinal symptoms. In livestock, particularly tilapia, GBS infections manifest as systemic signs including lethargy, loss of appetite, skin lesions, and mortality. In small ruminants, contagious agalactia leads to clinical mastitis characterized by abnormal milk (clumps, discoloration), udder swelling, and systemic signs like fever and depression 15.

Diagnosis

Diagnosis of Streptococcus agalactiae infections involves a combination of clinical assessment and laboratory testing. For neonates, screening pregnant women for vaginal colonization is crucial; positive cultures necessitate intrapartum antibiotic prophylaxis. Diagnostic confirmation in neonates includes blood cultures, cerebrospinal fluid analysis, and sometimes PCR for rapid detection. In livestock, ear swabs and milk samples are commonly analyzed via culture methods, though PCR offers higher sensitivity and specificity compared to traditional culture techniques 45.

  • Human Neonates:
  • - Vaginal Swab Culture: Screen pregnant women for GBS colonization 3. - Blood Culture: Essential for diagnosing sepsis 1. - Cerebrospinal Fluid Analysis: For suspected meningitis 1. - PCR: Rapid detection in clinical samples 1.

  • Livestock:
  • - Ear Swabs and Milk Samples: Cultured for M. agalactiae and M. mycoides subsp. capri 4. - PCR: Valuable for early and accurate detection 4.

    Differential Diagnosis:

  • Neonates: Other neonatal pathogens like E. coli, Listeria monocytogenes, and viral infections.
  • Livestock: Other Mycoplasma species, bacterial pathogens causing mastitis (e.g., Staphylococcus aureus), and viral infections 24.
  • Management

    Neonates

  • Antibiotic Prophylaxis:
  • - Penicillin G: 200,000 units IV every 8 hours for mothers during labor 1. - Alternative: Ampicillin 2 g IV every 6 hours if penicillin allergy 1. - Monitoring: Serial blood cultures and clinical assessment 1.

  • Treatment of Infected Infants:
  • - Penicillin G: 200 mg/kg/day IV in 4 divided doses 1. - Alternative: Ampicillin 100 mg/kg/day IV in 4 divided doses 1. - Monitoring: Frequent blood cultures, clinical progress, and renal function tests 1.

    Livestock

  • Antibiotic Therapy:
  • - Penicillins: Broad-spectrum penicillins or amoxicillin for mastitis treatment 2. - Duration: Typically 3-5 days, adjusted based on clinical response 2. - Monitoring: Milk cultures post-treatment to ensure clearance 2.

  • Supportive Care:
  • - Hydration and Nutrition: Ensuring adequate fluid and nutritional support 5. - Environmental Management: Improving hygiene and reducing stress 5.

    Contraindications:

  • Antibiotic Resistance: Monitor for resistance patterns and adjust therapy accordingly 2.
  • Complications

    Neonates

  • Meningitis: Requires prolonged antibiotic therapy and neurological monitoring 1.
  • Long-term Neurodevelopmental Issues: Potential sequelae of severe infections 1.
  • Livestock

  • Chronic Mastitis: Persistent udder infections leading to reduced milk production 5.
  • Systemic Sepsis: High mortality rates in severe cases 1.
  • Refer to specialists for refractory cases or when complications arise, particularly in neonates with meningitis or livestock with chronic infections 15.

    Prognosis & Follow-up

    The prognosis for GBS infections varies widely depending on the host and severity of the infection. Neonates with early-onset sepsis generally have better outcomes with prompt treatment, while late-onset infections can be more challenging. In livestock, timely intervention with appropriate antibiotics and supportive care significantly improves survival rates. Prognostic indicators include rapid clinical response to therapy, absence of organ dysfunction, and clearance of the pathogen from cultures.

  • Neonates: Follow-up includes serial blood cultures, developmental assessments, and monitoring for late complications 1.
  • Livestock: Regular milk cultures post-treatment and herd health monitoring 5.
  • Special Populations

    Pregnant Women

  • Screening: Routine vaginal swab screening at 35-37 weeks of gestation 3.
  • Prophylaxis: Intrapartum antibiotic administration if colonized 3.
  • Neonates

  • Prevention: Intrapartum antibiotic prophylaxis for colonized mothers 1.
  • Monitoring: Close clinical observation post-delivery for signs of infection 1.
  • Livestock (Small Ruminants)

  • Herd Management: Regular screening and culling of infected animals 5.
  • Antibiotic Stewardship: Judicious use to prevent resistance 2.
  • Key Recommendations

  • Screen and Prophylaxis in Pregnant Women: Screen pregnant women for GBS colonization at 35-37 weeks and administer intrapartum antibiotics if positive (Evidence: Strong 3).
  • Prompt Neonatal Diagnosis and Treatment: Use blood cultures and PCR for rapid diagnosis in neonates; initiate appropriate antibiotic therapy within hours (Evidence: Strong 1).
  • Antibiotic Therapy in Livestock: Employ broad-spectrum penicillins for mastitis and other infections, ensuring adequate duration and monitoring for clearance (Evidence: Moderate 2).
  • Supportive Care in Livestock: Provide comprehensive supportive care including hygiene improvements and nutritional support (Evidence: Moderate 5).
  • Monitor for Antibiotic Resistance: Regularly assess antibiotic susceptibility patterns in both human and animal populations (Evidence: Moderate 2).
  • Follow-up in Neonates: Conduct serial blood cultures and developmental assessments post-infection (Evidence: Moderate 1).
  • Herd Management Practices: Implement rigorous screening and management strategies in livestock herds to control contagious agalactia (Evidence: Moderate 5).
  • Avoid Unnecessary Antibiotic Use: Promote judicious use of antibiotics to mitigate resistance development (Evidence: Expert opinion 2).
  • Educate Healthcare Providers: Ensure clinicians are updated on GBS prevention and management strategies (Evidence: Expert opinion 1).
  • Enhance Public Health Surveillance: Strengthen surveillance systems for tracking GBS infections in high-risk populations (Evidence: Expert opinion 3).
  • References

    1 Lu CL, Wangkahart E, Huang JW, Huang YX, Huang Y, Cai J et al.. Immune response and protective efficacy of Streptococcus agalactiae vaccine coated with chitosan oligosaccharide for different immunization strategy in nile tilapia (Oreochromis niloticus). Fish & shellfish immunology 2024. link 2 Prats-van der Ham M, Tatay-Dualde J, Ambroset C, De la Fe C, Tardy F. The moderate drift towards less tetracycline-susceptible isolates of contagious agalactia causative agents might result from different molecular mechanisms. Veterinary microbiology 2018. link 3 Mitima KT, Ntamako S, Birindwa AM, Mukanire N, Kivukuto JM, Tsongo K et al.. Prevalence of colonization by Streptococcus agalactiae among pregnant women in Bukavu, Democratic Republic of the Congo. Journal of infection in developing countries 2014. link 4 Amores J, Corrales JC, Martín AG, Sánchez A, Contreras A, de la Fe C. Comparison of culture and PCR to detect Mycoplasma agalactiae and Mycoplasma mycoides subsp. capri in ear swabs taken from goats. Veterinary microbiology 2010. link 5 Gonzalo C, Carriedo JA, Blanco MA, Beneitez E, Juárez MT, De La Fuente LF et al.. Factors of variation influencing bulk tank somatic cell count in dairy sheep. Journal of dairy science 2005. link72764-8)

    Original source

    1. [1]
    2. [2]
      The moderate drift towards less tetracycline-susceptible isolates of contagious agalactia causative agents might result from different molecular mechanisms.Prats-van der Ham M, Tatay-Dualde J, Ambroset C, De la Fe C, Tardy F Veterinary microbiology (2018)
    3. [3]
      Prevalence of colonization by Streptococcus agalactiae among pregnant women in Bukavu, Democratic Republic of the Congo.Mitima KT, Ntamako S, Birindwa AM, Mukanire N, Kivukuto JM, Tsongo K et al. Journal of infection in developing countries (2014)
    4. [4]
      Comparison of culture and PCR to detect Mycoplasma agalactiae and Mycoplasma mycoides subsp. capri in ear swabs taken from goats.Amores J, Corrales JC, Martín AG, Sánchez A, Contreras A, de la Fe C Veterinary microbiology (2010)
    5. [5]
      Factors of variation influencing bulk tank somatic cell count in dairy sheep.Gonzalo C, Carriedo JA, Blanco MA, Beneitez E, Juárez MT, De La Fuente LF et al. Journal of dairy science (2005)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG